Molecular Imaging of HER2 Expression in Breast Cancer Using [99mTc]Tc-G3-(G3S)3C Before Chemo/Targeted Therapy


Tomsk National Research Medical Center of the Russian Academy of Sciences




Breast Cancer Female


Drug: [99mTc]Tc-G3-(G3S)3C

Study type


Funder types




Details and patient eligibility


The study should evaluate distribution of \[99mTc\]Tc-G3-(G3S)3C in patients with primary HER2-positive and HER2-negative breast cancer

Full description

Overall goal of the project: To determine HER2 expression level in primary breast cancer before neoadjuvant system therapy (chemotherapy or/and targeted therapy). Phase I. Distribution of [99mTc]Tc-G3-(G3S)3C in patients with primary breast cancer. The study should evaluate distribution of [99mTc]Tc-G3-(G3S)3C in patients with primary HER2-positive and HER2-negative breast cancer.


10 estimated patients




18 to 80 years old


No Healthy Volunteers

Inclusion criteria

  1. Subject is > 18 years of age

  2. Availability of results from HER2 status previously determined on material from the primary tumor and metastatic LN, either a. HER2-positive, defined as a DAKO HercepTest™ score of 3+ or FISH positive or b. HER2-negative, defined as a DAKO HercepTest™ score of 0 or 1+; or else if 2+ then FISH negative

  3. Hematological, liver and renal function test results within the following limits:

    • White blood cell count: > 2.0 x 109/L
    • Hemoglobin: > 80 g/L
    • Platelets: > 50.0 x 109/L
    • ALT, ALP, AST: =< 5.0 times Upper Limit of Normal
    • Bilirubin =< 2.0 times Upper Limit of Normal
    • Serum creatinine: Within Normal Limits
  4. A negative pregnancy test for all patients of childbearing potential. Sexually active women of childbearing potential participating in the study must use a medically acceptable form of contraception for at least 30 days after study termination

  5. Subject is capable to undergo the diagnostic investigations to be performed in the study

  6. Informed consent

Exclusion criteria

  1. Any system therapy (chemo-/targeted therapy)
  2. Second, non-breast malignancy
  3. Active current autoimmune disease or history of autoimmune disease
  4. Active infection or history of severe infection within the previous 3 months (if clinically relevant at screening) 4. Known HIV positive or chronically active hepatitis B or C
  5. Administration of other investigational medicinal product within 30 days of screening
  6. Ongoing toxicity > grade 2 from previous standard or investigational therapies, according to US National Cancer Institute's

Trial design

Primary purpose




Interventional model

Single Group Assignment


None (Open label)

10 participants in 1 patient group

The tested injected doses of [99mTc]Tc-G3-(G3S)3C 3000 μg
Experimental group
At least five (5) evaluable subjects with HER2-positive status and at least five (5) subjects with HER2-negative status have to be enrolled in the study for each tested protein dose. The tested injected dose 3000 μg. Subjects withdrawn from the study for any reason will be replaced.
Drug: [99mTc]Tc-G3-(G3S)3C

Trial contacts and locations



Data sourced from

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems